Catalucci Chiara, Bianchi Marco Luigi, Treggiari Elisabetta, Pieri Marta, Ruess Katja, Valenti Paola
Oncology Service, Clinica Veterinaria Malpensa AniCura, Samarate, Italy.
Oncology Service, Clinica Veterinaria Nervianese, Nerviano, Italy.
Vet Comp Oncol. 2024 Sep;22(3):422-428. doi: 10.1111/vco.12990. Epub 2024 Jun 18.
Multiagent chemotherapy is considered the most effective treatment for canine high-grade lymphoma; however, due to cost and time requirements, single-agent protocols have also been described. The aim of our study was to evaluate the outcome and prognostic factors of dogs affected by multicentric lymphoma treated with lomustine and prednisolone as first-line treatment. Cases of medium-large-cell multicentric lymphoma treated with lomustine and prednisolone were included in the study. Response to therapy, time to progression (TTP), median disease-free interval (MDFI) and median survival time (MST) were retrospectively described. Thirty cases were included. Eleven (36.67%) were T cell, 11 (36.67%) were B cell and 8 (26.66%) had unknown immunophenotype. The overall response rate (RR) was 87%, with 15 patients achieving CR (50%) and 11 patients PR (37%). The median TTP, MDFI and MST were 42, 63 and 90 days, respectively. The only factor significantly associated with MDFI and MST was the stage. Dogs with multicentric lymphoma treated with lomustine and prednisolone have lower RR, TTP, MDFI and MST compared with dogs receiving multiagent protocols. Based on the short-lasting response, this study confirms that this protocol might have minimal utility beyond palliation.
多药联合化疗被认为是犬高级别淋巴瘤最有效的治疗方法；然而，由于成本和时间要求，也有单药治疗方案的报道。我们研究的目的是评估以洛莫司汀和泼尼松龙作为一线治疗的多中心淋巴瘤犬的治疗结果和预后因素。本研究纳入了接受洛莫司汀和泼尼松龙治疗的中大型细胞多中心淋巴瘤病例。对治疗反应、疾病进展时间（TTP）、无病生存期（MDFI）中位数和总生存期（MST）中位数进行了回顾性描述。共纳入30例病例。11例（36.67%）为T细胞型，11例（36.67%）为B细胞型，8例（26.66%）免疫表型未知。总缓解率（RR）为87%，15例患者达到完全缓解（CR，50%），11例患者达到部分缓解（PR，37%）。TTP、MDFI和MST中位数分别为42天、63天和90天。与MDFI和MST显著相关的唯一因素是分期。与接受多药联合方案治疗的犬相比，接受洛莫司汀和泼尼松龙治疗的多中心淋巴瘤犬的RR、TTP、MDFI和MST较低。基于短期反应，本研究证实该方案除了姑息治疗外可能效用极小。
